The human histamine H 4 receptor (hH 4 R), coexpressed with G␣ i2 and G␤ 1 ␥ 2 in Sf9 insect cells, is highly constitutively active, and thioperamide [THIO; 
number of wild-type GPCRs, e.g., for the ␦-opioid receptor (Costa and Herz, 1989) , the human formyl peptide receptor FPR-26 (Wenzel-Seifert et al., 1998) , the cannabinoid CB 1 receptor (Bouaboula et al., 1997) , and the histamine receptors H 1 R (Leurs et al., 2002) , H 2 R (Alewijnse et al., 1998) , H 3 R (Wieland et al., 2001) , and H 4 R (Liu et al., 2001; ). Constitutive activity is not only a common property of wild-type GPCRs, but also is the cause of several diseases (Seifert and Wenzel-Seifert, 2002) . Even cancerous cell transformation may be caused by a long-term elevation of second messengers, resulting from constitutive activity of overexpressed receptors (Seifert and Wenzel-Seifert, 2002; Kenakin, 2004) . Thus, it is obvious that the targeted development of inverse agonistic drugs will gain more and more importance. However, for most receptors only very little is known about the structural requirements governing inverse agonism and neutral antagonism. Although efforts have been made to establish structure-activity relationships for inverse agonists at GPCRs (Soudijn et al., 2005) , most drug development programs are still not designed to systematically investigate this issue.
As we recently reported , the hH 4 R is highly constitutively active when coexpressed with G␣ i2 and G␤ 1 ␥ 2 in Sf9 insect cells using the baculovirus expression system. In steady-state GTPase and [ 35 S]GTP␥S binding assays thioperamide (THIO) was found to be one of the most efficacious inverse agonists at the hH 4 R. The benzimidazole derivative JNJ-7777120 [1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methyl-piperazine], which behaves as a neutral hH 4 R antagonist in reporter gene assays (Lim et al., 2005) , showed a partial inverse agonistic effect in our system, reaching ϳ30% of the THIO efficacy .
In contrast to the hH 3 R, which plays an important role in neurological and psychiatric diseases, the hH 4 R is an interesting drug target for the therapy of inflammation, allergy, and autoimmune disorders (Tiligada et al., 2009 ). Specifically, the hH 4 R is involved in the pathogenesis of pruritus and asthma (Thurmond et al., 2008; Neumann et al., 2010) . In past years, a large number of structurally diverse compounds targeting the hH 4 R were developed with an increasing focus on the aminopyrimidine scaffold Smits et al., 2009) . If hH 4 R-related diseases are caused or promoted by extraordinarily high constitutive hH 4 R activity, inverse agonists at the hH 4 R would be an interesting therapeutic option. However, if inverse agonists caused receptor up-regulation, resulting in rebound effects after discontinuation of the therapy, neutral hH 4 R antagonists would be preferred.
Therefore, we started a project to investigate structureactivity relationships for inverse agonism and neutral antagonism at the hH 4 R. Here, we report on the investigation of a series of 25 indole, benzimidazole, and thienopyrrole derivatives that were described previously as hH 4 R ligands (Venable et al., 2005) and are structurally related to the reference compound JNJ-7777120. We characterized the compounds by using Sf9 cell membranes coexpressing the hH 4 R with G␣ i2 and G␤ 1 ␥ 2 . We performed steady-state GTPase assays and highaffinity radioligand binding assays with [ 
Materials and Methods
Materials. The baculoviruses encoding the N-terminally FLAG and C-terminally hexahistidine-tagged hH 4 R were prepared as described recently . Recombinant baculovirus for the unmodified versions of the G␤ 1 ␥ 2 subunits was a kind gift of Dr. P. Gierschik (Department of Pharmacology and Toxicology, University of Ulm, Ulm, Germany). Baculovirus encoding G␣ i2 was donated by Dr. A. G. Gilman (Department of Pharmacology, University of Southwestern Medical Center, Dallas, TX). The antibody selective for G␣ i1/2 was purchased from Calbiochem (San Diego, CA), and the M1 anti-FLAG antibody was obtained from Sigma-Aldrich (St. Louis, MO). The series of H 4 R antagonists investigated in this article were synthesized as described previously (Venable et al., 2005) and provided by Johnson and Johnson Pharmaceutical Research and Development (San Diego, CA). Stock solutions (10 mM) were prepared in Me 2 SO. The dilution series was prepared in 10% (v/v) dimethyl sulfoxide (DMSO). Because of low solubility, for compounds 9 and 10 50% (v/v) DMSO was used for the preparation of the 1 mM solution. THIO was obtained from Tocris Bioscience (Bristol, UK), and the dilution series was prepared in 10% DMSO. The final concentration of DMSO in the sample was 5% for compounds 9 and 10 and 1% for the other compounds. [
3 H]HA (specific activity 14.2-18.1 Ci/mmol) was obtained from PerkinElmer Life and Analytical Sciences (Waltham, MA). We prepared [␥- 32 P]GTP by using GDP and [ 32 P] (orthophosphoric acid, 150 mCi/ml; obtained from PerkinElmer Life and Analytical Sciences) according to a previously described enzymatic labeling procedure. All other reagents were of the highest purity available from standard suppliers. Radioactive samples were counted in a PerkinElmer Life and Analytical Sciences Tricarb 2800TR liquid scintillation analyzer.
Generation of Recombinant Baculoviruses, Cell Culture, and Membrane Preparation. Sf9 cells were cultured in 250-or 500-ml disposable Erlenmeyer flasks at 28°C under rotation at 150 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA) supplemented with 5% (v/v) fetal calf serum (Biochrom, Berlin, Germany) and 0.1 mg/ml gentamicin (Lonza Walkersville, Inc., Walkersville, MD). Cells were maintained at a density of 0.5 to 6.0 ϫ 10 6 cells/ml. Recombinant baculoviruses were generated in Sf9 cells by using the BaculoGOLD transfection kit (BD Pharmingen, San Diego, CA) according to the manufacturer's instructions. After initial transfection, high-titer virus stocks were generated by two sequential virus amplifications. The supernatant fluid from the second amplification was stored under light protection at 4°C and used as routine virus stock for membrane preparations.
Infection of the cells with baculoviruses encoding hH 4 R, G␣ i2 , and G␤ 1 ␥ 2 was performed as described previously (Preuss et al., 2007) . Sf9 membranes were prepared as described previously (Gether et al., 1995) , using 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 g/ml benzamidine, and 10 g/ml leupeptin as protease inhibitors. Membranes were suspended in binding buffer (12.5 mM MgCl 2 , 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). All membrane preparations were stored at Ϫ80°C until use.
[ 3 H]HA Binding Experiments. Before the experiments, membranes were sedimented by a 10-min centrifugation at 4°C and 13,000 rpm and resuspended in binding buffer (12.5 mM MgCl 2 , 1 mM EDTA, and 75 mM Tris/HCl, pH 7.4). For competition binding experiments 10 nM [ 3 H]HA and four to six appropriate concentrations between 1 nM and 100 M of the test compound were used. Nonspecific binding was determined in the presence of THIO (10 M). Incubations were performed for 60 min at 25°C with shaking at 250 rpm. Bound radioligand was separated from free radioligand by filtration through GF/C filters pretreated with 0.3% (m/v) polyethyleneimine and washed three times with 2 ml of ice-cold binding buffer (4°C). Filter-bound radioactivity was determined by liquid scintillation counting.
Steady-State GTPase Assay. Steady-state GTPase assays were essentially performed as described previously . The samples did not contain NaCl, and the reaction temperature was 25°C. Inverse agonist pEC 50 values were determined in the absence of HA, whereas pK b values were calculated from pIC 50 values determined in the presence of agonist (HA, 100 nM). For all assays four to six appropriate concentrations between 1 nM and 100 M of the test compound were used. To quantify efficacies, THIO (10 M) was used as reference for the maximum inverse agonistic effect.
Molecular Modeling. Based on the crystal structure of the human ␤ 2 adrenergic receptor a homology model of the inactive hH 4 R was generated as described previously (Deml et al., 2009 ). Glu 5.46 was modeled in its protonated state, as proposed (Jongejan et al., 2008) . The unsubstituted compound (compound 2) was docked manually into the binding pocket of hH 4 R. Subsequently, molecular dynamic simulations were performed as described previously (Strasser et al., 2008) , including the natural surrounding of the receptor, such as lipid bilayer and water. For all molecular dynamic simulations, the software Gromacs (http://www.gromacs.org) was used.
Determination of Descriptors for Quantitative StructureActivity Relationship. To search for dependence of efficacy, several ligand-specific descriptors, such as logP, polar surface area, molar refractivity, molar volume, refraction index, and polarizability, were calculated (ACD/PhysChem, release 11.0; ACD Labs, Toronto, Canada).
Miscellaneous. Protein concentrations were determined with the Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules, CA). Membrane proteins were separated on SDS polyacrylamide gels containing 10 or 12% (m/v) acrylamide. Proteins were transferred onto Trans-Blot nitrocellulose membranes (Bio-Rad Laboratories) and reacted with M1 anti-FLAG (1:1000) or anti-G␣ 1/2 (1:1000). Protein bands were visualized by enhanced chemiluminescence (Pierce Chemical, Rockford, IL) using goat anti-mouse IgG (SigmaAldrich; 1:2000) or donkey anti-rabbit IgG (GE Healthcare, Little Chalfont, Buckinghamshire, UK; 1:10,000), both coupled to horseradish peroxidase.
Radioligand competition experiments and steady-state GTPase assays were analyzed by nonlinear regression with Prism 5.01 software (GraphPad Software Inc., San Diego, CA). For every compound the curves of all assays were merged in one file, and a global fit over all data was performed. All values are given as means Ϯ S.E.M. Significance was defined as p Ͻ 0.05 (confidence interval 95%). In the case of multiple t tests (comparisons of pEC 50 with pK i or pK b ) the Bonferroni correction was applied (44 t tests), resulting in a new significance level of p Ͻ 0.001.
Results
Radioligand Binding. The compounds were characterized in radioligand competition binding assays using [
3 H]HA (10 nM) and membranes from Sf9 cells coexpressing the hH 4 R with G␣ i2 and G␤ 1 ␥ 2 . As shown in Fig. 1A , there is a good correlation (p Ͻ 0.0001; r 2 ϭ 0.88; slope 1.12 Ϯ 0.09) between the pK i values determined in the Sf9 cell system and previously reported results (Venable et al., 2005) , indicating that the rank order of affinity within the compound series was retained in our experimental system. However, the pK i values determined in Sf9 cell membranes were on average by 0.68 log units lower than the literature data.
Our results show ( Table 1 ) that in the series of piperazinemethylated and R 5 -monosubstituted indole derivatives the pK i values are influenced by the R 5 residues in the following rank order (compound numbers in parentheses): Cl (4) Ͼ Br (5) ϳ F (3) Ͼ CH 3 (6) ϳ NH 2 (8) ϳ H (2) Ͼ Ͼ OCH 3 (7) ϳ CF 3 (9). Thus, halogen substitution in position R 5 increases binding affinity, whereas an OCH 3 or a CF 3 residue in this position considerably reduces the pK i value. Introduction of an additional F or Cl in position R 7 of compound 3 or 4 yields the structures 10 and 11 with slightly (-0.30 log units) reduced affinity (Table 1) . By contrast, R 5 /R 7 disubstitution with CH 3 (12) did not significantly alter the binding affinity, compared with the corresponding R 5 -monosubstituted compound 6. This indicates that substituents in R 7 are well tolerated without major reduction of affinity (Table 1 ). In fact, R 7 monosubstitution with NH 2 (15) and CH 3 (16) is even beneficial and increases the binding affinity by ϳ0.5 log units, compared with the totally unsubstituted compound 2 (Table 1) .
We also investigated different positions of a Br residue in the ring system and found that the pK i value correlates with the position of Br in the rank order R 5 (5) Ͼ Ͼ R 6 (13) ϳ R 7 (14), with ϳ1 log unit affinity difference between Br in R 5 and R 6 (Table 1 ). This shows again that halogen substitution in position R 5 is favored and leads to compounds with high binding affinity. Compound 4, the experimentally most widely used H 4 R antagonist JNJ-7777120 (Jablonowski et al., 2003; Thurmond et al., 2004) , shows the highest affinity in the investigated series and is substituted with Cl in position R 5 .
When the indole scaffold is replaced by a benzimidazol (2005) and relationships between inverse agonist pK i , pEC 50 , and pK b values. All data shown were determined in Sf9 cell membranes, coexpressing hH 4 R, G␣ i2 , and G␤ 1 ␥ 2 . A, correlation between the pK i values determined by radioligand binding in Sf9 cell membranes and the previously reported results (Venable et al., 2005 jpet.aspetjournals.org structure (Table 2) , in most cases the affinity is reduced by at least 0.3 log units (compounds 17, 18, 20, and 21 in Table 2 versus compounds 2, 3, 6, and 16 in Table 1 ). Only when a CF 3 substituent is located in position R 5 , a change from the indole (9) to the benzimidazole (19) structure leads to an increase of the pK i by ϳ0.3 log units. Replacement of the phenyl moiety of the indole scaffold by the bioisosteric thiophene ring yielded the thienopyrrol series shown in Table 2 . When completely unsubstituted, this change of scaffold led to a reduction of the pK i value by ϳ0.5 log units (indole derivative 2 in Table 1 versus thienopyrrole derivative 23 in Table  2 ). Compound 25, which is substituted with Cl in position R 4 and CH 3 in R 5 shows an affinity comparable with the (R 5 -) Cl-substituted compound 4 (JNJ-7777120). Steady-State GTPase Assays: Efficacies. We also investigated the functional properties of the compounds in steady-state GTPase assays. As shown in Tables 1 and 2 , the majority of compounds exhibited inverse agonism with efficacies between 15 and 62% of the effect of the hH 4 R inverse agonist THIO. It is noteworthy that we also found three neutral antagonists (compounds 9, 14, and 19). Figure 2 shows examples for compounds with effects between neutral antagonism and 60 to 70% of the THIO effect. As suggested by the structures of 9 (indole derivative) and 19 (benzimidazole derivative), a CF 3 residue in position R 5 favors neutral antagonism. Compound 14, which has a Br substituent located in position R 7 , is also a neutral antagonist. Replacement of Br in R 7 by either H (2), NH 2 (15), or CH 3 (16) results in inverse agonists with efficacies of Ϫ0.40 (2), Ϫ0.37 (15), or Ϫ0.29 (16). This indicates that neutral antagonism requires an electronegative, electron-withdrawing substituent in position R 7 .
Relatively high inverse agonistic efficacies (range between Ϫ0.45 and Ϫ0.65) were found for compounds 1, 3, 10, 11, 17, 21, and 22. It is noteworthy that compound 1 is not methylated at the piperazine ring. Although the piperazine methyl substitutent increases affinity in radioligand binding (compound 1 versus 2 in Table 1) , it is obviously not necessary for a large inverse agonistic effect. Within the series of R 5 -monosubstituted indole derivatives (compounds 2-9, Table 1), the efficacy depends on the R5 substituent in the following rank order:
When in the structures of 3 (R 5 ϭ F), 4 (R 5 ϭ Cl), or 6 (R 5 ϭ CH 3 ) a second F (10), Cl (11), or CH 3 (12) substituent is introduced in position R 7 this does only slightly change inverse agonistic efficacy by 0.10 to 0.20 units. The Br substituent can be moved from R5 (5) to R6 (13) without a significant change in efficacy (Table 1) . However, as already mentioned, Br in position R 7 leads to a complete loss of inverse agonistic effect, yielding a neutral antagonist.
In the benzimidazole series, for compounds 18, 19, and 20 (Table 2) , the efficacies were not significantly different from those of the corresponding indole compounds 3, 6, and 9 (Table 1) . Only in case of the completely unsubstituted and the (R 7 -) CH 3 -substituted compounds did a change from the indole structure (2 and 16 in Table 1 ) to the benzimidazole scaffold (17 and 21 in Table 2 ) increase inverse agonistic efficacy by 0.15 to 0.20. The compounds of the thienopyrrole series show only moderate to low inverse agonism. The thienopyrroles 24 and 25 and the indole derivative 12 represent Tables 1 and 2 indicate that most of the compounds show tendency toward increased pK i and pK b values compared with the corresponding pEC 50 values. This is also demonstrated in Fig. 1 , B and D by the reduced slope of the regression lines and by the fact that the majority of data points are located left of the diagonal line. This trend reached significance (p Ͻ 0.001, t test with Bonferroni correction for the total number of t tests) for compounds 3 and 11 (pK i Ͼ Ͼ pEC 50 ; filled circles in Fig. 1B) and compounds 1, 3, 7 , 10, 11, and 17 (pK b Ͼ Ͼ pEC 50 ; filled circles in Fig. 1D ). The pK b or pK i values that are significantly higher than the corresponding pEC 50 values are also in bold in Tables 1 and 2 .
The correlation between pEC 50 values and pK b values was significant, but widely scattered ( Fig. 1D ; p Ͻ 0.001; r 2 ϭ 0.36). The best correlation was found for the pK b values from antagonist mode GTPase assays compared with the pK i values from radioligand competition binding ( Fig. 1C ; p Ͻ 0.0001; r 2 ϭ 0.66). Binding Mode of Compound 2. Molecular dynamics revealed a stable interaction between compound 2 and the receptor (Fig. 3A) . The positively charged terminal amino 6.48 in its vertical conformation, which is proposed to be an essential part of the so-called rotamer toggle switch (Shi et al., 2002) and is considered typical for the inactive state of a biogenic amine receptor. Thus, the binding mode of 2 described here differs significantly from that of the related compound 4, which has been described previously (Jójá rt et al., 2008) . These significant differences in binding mode with regard to the structurally highly related compounds 2 and 4 may be explained by different hH 4 R models. The model of Jójá rt et al. (2008) is based on the crystal structure of bovine rhodopsin, whereas the hH 4 R model used within this study is based on the crystal structure of h␤ 2 R. Another reason for the different findings may be the differences in simulation and docking protocol.
A comparison of the backbone of TMVII of the compound 2-hH 4 R complex with the backbone of TMVII of the ligandfree hH 4 R revealed a slight shift of TMVII away from TMVI (Fig. 3B) . The indole moiety of the ligand switches into the pocket neighbored to Trp 6.48 and thus induces a slight movement of Trp 6.48 toward TMVII. As a consequence, TMVII is slightly shifted away from TMVI. Furthermore, the simulations revealed two small pockets in the R5 and R7 positions of the indole derivatives (Fig. 3C) . These pockets can be filled with additional substituents in the corresponding positions. Docking of 11 into the binding pocket reveals that both chlorine atoms optimally fit into these additional pockets (Fig.  3D) . Thus, the interactions between ligand and receptor are not disturbed. Further docking studies with compound 7 (data not shown) revealed that the space-filling methoxy moiety does not fit into the additional pocket. Because the benzimidazole derivatives can exist in two tautomeric states, both tautomers of derivative 20 were docked into the binding pocket of hH 4 R. The first tautomer (methyl moiety in R5 position) fit well into the binding pocket with its additional methyl moiety, and no loss in interaction was observed (Fig.  3E) . In contrast, the second tautomer (methyl moiety in R6 position) did not fit into the binding pocket, because in the position of the methyl moiety, there was no additional space left (Fig. 3F) . Further simulations showed (data not shown) that the second tautomer (methyl moiety in R6 position) shifted away from TMVI. As a consequence, the interaction with Glu 5.46 was lost. It is possible that the indole moiety rotates approximately 180°. In this conformation, there is sufficient space for the additional methyl group, but again, because of the rotation of the indole, the interaction between the NH of the indole and Glu 5.46 was lost. Dependence of the Efficacy of Compounds 2-9 on Molar Volume. To describe the efficacy of the indole derivatives with differences in substitution pattern in R5, we calculated the descriptors logP, polar surface area, molar refractivity, molar volume (van der Waals volume of 1 mol), refraction index, and polarizability. The calculations showed that the efficacy significantly depends on the molar volume of the ligand, but not on the other properties mentioned above. A correlation of the molar volume with the efficacy for compounds 2-9 led to a linear relationship (Fig. 4) described by the following equation: efficacy ϭ Ϫ3.036 ͑Ϯ 0.591͒ ϩ 0.0129 ͑Ϯ 0.00279͒ V ͓cm 3 ͔ with the statistical parameters: n ϭ 8, r 2 ϭ 0.782, F ϭ 21.56, standard error of estimate ϭ 0.085, and p Ͻ 0.005. Thus, the efficacy of compounds 2-9, with variations in the substitution pattern in R5 position, strongly depends on the volume of the substituent. All other properties did not show any influence on efficacy. However, the efficacy of compounds 10-16 with different substitution patterns in R7 does not correlate with the molar volume or any of the other properties mentioned above. (green) and TMVII (green) represent the conformation without compound 2. In the ligand-receptor complex TMVII is slightly shifted away from TMVI. C, compound 2 in the binding pocket (gray). The dashed circles indicate the regions in the binding pocket with space left for substituents in position R5 and R7. D, compound 11 docked into the binding pocket of 2; both chlorines fill the additional spaces optimally (indicated by black arrows). E, compound 20 docked in its first tautomeric form into the binding pocket of 2; the additional methyl group fits optimally into the additional space of the binding pocket (indicated by a black arrow). F, compound 20 docked in its second tautomeric form into the binding pocket of 2; the additional methyl group (indicated by a black arrow) is too large and thus does not fit optimally in the additional space of the binding pocket (indicated by a dashed circle); the ligand is shifted away from TMVI (brown arrow).
Discussion
The extraordinarily high and Na ϩ -insensitive constitutive activity of the hH 4 R suggests that inverse agonists and neutral antagonists may behave differently in clinical conditions. If high constitutive receptor activity leads to pathological condition, then inverse hH 4 R agonists may be more effective than neutral antagonists. On the other hand, neutral antagonists could be advantageous, because they may induce less up-regulation of binding sites compared with inverse agonists.
Therefore, it is very important for the development of hH 4 R antagonistic drugs that the structural requirements for neutral antagonism and inverse agonism are elucidated, enabling the synthesis of tailored compounds with the intended quality of action. To learn more about structure-activity relationships for hH 4 R neutral antagonists and inverse agonists we investigated a series of 25 hH 4 R antagonists described previously as H 4 R ligands (Venable et al., 2005) . The compounds were characterized in the recently reported Sf9 insect cell-based test system, coexpressing hH 4 R with G␣ i2 and G␤ 1 ␥ 2 ). The expression level of G␣ i2 in Sf9 cells is more than 100-fold higher than the hH 4 R expression level . Thus, signal transduction of hH 4 R is not hampered by a limited G␣ i2 availability. It has to be emphasized that we determined inverse agonistic activity at the point of GDP/ GTP exchange, which is very proximal in the signal transduction cascade. Functional assays at more distal points, such as adenylyl cyclase or reporter gene assays, often suffer from nonlinear signal transduction, e.g., because of limited availability of distal signaling components. Such effects can bias determination of correct inverse agonistic activities.
Radioligand competition assays with [ 3 H]HA revealed a good correlation of our data with previously reported results (Venable et al., 2005) . It is noteworthy that among the 25 compounds investigated in our study three compounds (12%) were neutral antagonists, suggesting that neutral antagonism is rather exceptional. This is confirmed by a previously reported survey of 105 articles describing 380 antagonists acting on 73 GPCRs. Only 15% of these compounds acted as neutral antagonists (Kenakin, 2004) . The similar percentage of inverse agonists potentially indicates a general mechanism of regulation of constitutive activity that most GPCRs may have in common. It is noteworthy that the neutral antagonists identified in our studies all show very low affinities with pK i values approximately 6.50 (compound 14) or lower (compounds 9 and 19). We do not have an explanation for these data. There is no indication in the literature that neutral antagonism goes along with low affinity. In fact, some low-affinity H 4 R ligands are actually highly efficacious inverse agonists (Deml et al., 2009) .
All inverse agonists investigated in our study exhibited lower efficacies than the reference compound THIO, confirming that THIO is one of the most effective inverse hH 4 R agonists. However, as recently reported, THIO does not exert the maximum possible inverse agonistic effect , and a quinazoline derivative with higher inverse agonistic efficacy than THIO has been described previously . This compound is closely related to the structures investigated in our study, suggesting that small structural changes can largely affect inverse agonistic efficacy. This was also observed within our compound series. For instance, introduction of Br in position R 7 of the unsubstituted indole derivative 2 (efficacy ϭ Ϫ0.40) eliminates inverse agonism and produces the neutral antagonist 14. A similar sensitivity of inverse agonistic efficacy for subtle structural changes was described previously, e.g., for ␣ 1 AR antagonists (Rossier et al., 1999) or 5-HT 1B R antagonists (Gaster et al., 1998) .
Unexpectedly, we found a subset of compounds (filled circles in Fig. 1 , B and D) with pEC 50 values significantly lower than the pK i and/or pK b values. Such discrepancies are not unusual for inverse agonists (Table 3 ). The pK b values in our compound series were much closer to the pK i values than the pEC 50 values. Because pK b and pK i values were determined in the presence of HA, but pEC 50 values were determined in its absence, it is possible that some of the inverse agonists discriminate between the constitutively active receptor state and the active state stabilized by histamine. However, this phenomenon seems to be complex, because the pK i /pEC 50 difference was observed only in some hH 4 R inverse agonists. Also the cimetidine/famotidine pair in Table 3 (Alewijnse et al., 1998) confirms that even in the same system the EC 50 /K i ratio may show large variability. The literature examples shown in Table 3 for the cannabinoid CB 2 R (Ross et al., 1999) and the dopamine D 2 R (Roberts et al., 2004) show that systems with good correlation between EC 50 and K i values also exist. It is noteworthy that the difference in EC 50 /K i ratios obtained with the neutral D 2 R antagonist [ Table 3 show that the two-state model of receptor activation, which describes only one active and one inactive receptor state, is not sufficient to describe the pharmacological properties of inverse agonists. Hence, the model must be extended to include different active states, dependent on whether the receptor is agonist-activated or constitutively active. Other data confirm that the two-state model of receptor activation has to be expanded into a more complex model. For example, the replacement of GTP by xanthosine 5Ј-triphosphate switches the effect of ICI 118551 [erythro-DL-1-(7-methylin- jpet.aspetjournals.org dan-4-yloxy)-3-isopropylaminobutan-2-ol] at the ␤ 2 AR-Gs␣ s fusion protein expressed in Sf9 cells in the cAMP assay from inverse agonism to partial agonism (Seifert et al., 1999) . Furthermore, certain ␤ 2 AR agonists act as partial agonists or inverse agonists depending on whether the functional assay is performed in intact cells or cell membranes (Chidiac et al., 1994) .
Molecular dynamic simulations revealed a stable binding mode for 2, different from the already published binding mode of the related compound 4 (Jójá rt et al., 2008) . However, the binding mode described in this work is similar to the recently published binding mode of clozapine at hH 4 R (Jongejan et al., 2008) . The indole or the benzimidazole moiety of the compounds described here are embedded in a small pocket, parallel to the indole moiety of Trp 6.48 in its inactive, more vertical conformation. A conformational change, the rotamer toggle switch of the highly conserved amino acids Trp 6.48 and Phe 6.52 is necessary for GPCR activation (Crocker et al., 2006; Strasser et al., 2008) . Molecular dynamic simulations revealed that the hydrophobic interaction between the benzimidazole or indole moiety of the compounds stabilizes the inactive conformation of the Trp 6.48 . Because of this interaction between the ligand and Trp 6.48 , Trp 6.48 cannot switch into its active, vertical conformation. Thus, the inverse agonism or antagonism of the analyzed compounds can be explained. The exchange of the hydrogen in R5 and/or R7 position in the indole derivatives into more space-filling substituents, such as chlorine, as given in compounds 4 and 11, leads to an increase in affinity, caused by an increase in contact area between ligand and receptor. If the substituent is too large, such as in compound 7, a decrease in affinity is observed. However, because no significant dependence between affinity and molar volume of compounds 2-9 could be observed further, and as yet unknown descriptors may be relevant. By contrast, the efficacy of compounds 2-9 depends significantly on the molar volume. With decreasing molar volume, corresponding to a decreasing volume of substituent in R5 position, a significant decrease in efficacy is observed (Fig. 4) . Thus, small substituents in R5 position shift the equilibrium between inactive and active conformation toward the inactive state.
It should be noted that our study comprised a relatively small number of compounds. Important substitution patterns (e.g., benzimidazoles derivatives substituted in analogy to the indole derivatives) were, most unfortunately and despite substantial efforts, not available to us. Therefore, our study does not allow more detailed conclusions about the interactions at the binding site. Binding modes of structurally completely different H 4 R inverse agonists, e.g., of thioperamide or some 2,4-diaminopyrimidines , are not predictable from our results. In addition, establishing analogies between the binding mode of the JNJ compounds and other compounds, would lead to an extensive modeling study, which is beyond the scope of this article.
Nevertheless, to the best of our knowledge, our study is one of the first that systematically investigated structure-activity relationships of inverse GPCR agonists, using structurally closely related compounds. Our experiments showed that explaining the impact of structural alterations on the pharmacological properties of inverse agonists is much more difficult than expected, because structure-activity relationships could be established only for substituents in position R5 of the indole-derived compounds. Seemingly, the sole determination of pK b and pK i values is not sufficient to establish structure-activity relationships for inverse agonists. Similarly to previously reported results for 2,4-diaminopyrimidine-derived hH 4 R ligands , our results show that small changes in molecular structure lead to extensive efficacy and potency differences, caused by yet unpredictable major changes in binding mode and receptor conformation. This could be elucidated by cocrystallization of hH 4 R with structurally diverse inverse agonists. The recently published crystal structure of the ␤ 2 adrenoceptor, cocrystallized with the inverse agonist carazolol (Cherezov et al., 2007; Rasmussen et al., 2007) , shows that this approach is possible.
